Role of Axumin PET Scan in Germ Cell Tumor

University of Texas Southwestern Medical Center10 enrolled

Overview

Investigators will use Axumin PET/CT to help with the imaging modalities to determine the presence of occult retroperitoneal disease.

Investigators aim to perform a prospective study of anti-18F-FACBC PET/CT in patients with NSGCT prior to RPLND, either in the primary setting or in the post-chemotherapy setting. We will correlate histopathologic outcomes from the RPLND specimen and clinical outcomes of recurrence during follow-up to identify the accuracy of anti-18F-FACBC PET/CT in these settings.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Testis Cancer Germ Cell Tumor Testicular Cancer Germ Cell Tumor of Testis Germ Cell Tumor, Testicular, Childhood Testicular Neoplasms Testicular Germ Cell Tumor

Eligibility

Sex: MALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with histologically confirmed NSGCT after orchiectomy who are scheduled to undergo primary RPLND or post-chemotherapy RPLND * Patients must be over 18 years old and capable and willing to provide informed consent. * Medically stable as judged by patient's physician. * Life expectancy must be estimated at \> 6 months. * Patients must have an ECOG performance status of 0-3 (restricted to ECOG PS 0-2 if age \>70 years). * Patient must be able to lie still for a 20 to 30 minute PET/CT scan. Patients will be asked if they have problems or issues with lying flat Exclusion Criteria: * Patients with known allergic or hypersensitivity reactions to previously administered radiopharmaceuticals of similar chemical or biologic composition to anti-18F-FACBC are NOT eligible. * Patients with liver failure are NOT eligible. * Patients currently undergoing chemotherapy or chemotherapy within two weeks of anti-18F-FACBC PET/CT scan are NOT eligible

Outcomes

Primary Outcomes

Performance characteristics of Axumin PET scan in patients undergoing retroperitoneal lymph node dissection

Investigate the accuracy of anti-18F-FACBC PET/CT correlating with histopathologic outcomes

Time frame: Two years